• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

剂量探索研究中的非参数优化设计。

Non-parametric optimal design in dose finding studies.

作者信息

O'Quigley John, Paoletti Xavier, Maccario Jean

机构信息

Department of Mathematics, University of California, San Diego, CA 92093, USA.

出版信息

Biostatistics. 2002 Mar;3(1):51-6. doi: 10.1093/biostatistics/3.1.51.

DOI:10.1093/biostatistics/3.1.51
PMID:12933623
Abstract

We describe a non-parametric optimal design as a theoretical gold standard for dose finding studies. Its purpose is analogous to the Cramer-Rao bound for unbiased estimators, i.e. it provides a bound beyond which improvements are not generally possible. The bound applies to the class of non-parametric designs where the data are not assumed to be generated by any known parametric model. Whenever parametric assumptions really hold it may be possible to do better than the optimal non-parametric design. The goal is to be able to compare any potential dose finding scheme with the optimal non-parametric benchmark. This paper makes precise what is meant by optimal in this context and also why the procedure is described as non-parametric.

摘要

我们将非参数最优设计描述为剂量探索研究的理论金标准。其目的类似于无偏估计量的克拉美 - 罗界,即它提供了一个界限,一般来说超出这个界限就不太可能有改进。该界限适用于不假定数据由任何已知参数模型生成的非参数设计类别。只要参数假设确实成立,就有可能比最优非参数设计做得更好。目标是能够将任何潜在的剂量探索方案与最优非参数基准进行比较。本文明确了在此背景下最优的含义,以及为何该程序被描述为非参数的。

相似文献

1
Non-parametric optimal design in dose finding studies.剂量探索研究中的非参数优化设计。
Biostatistics. 2002 Mar;3(1):51-6. doi: 10.1093/biostatistics/3.1.51.
2
Optimal designs for estimating the most successful dose.用于估计最有效剂量的最优设计。
Stat Med. 2006 Dec 30;25(24):4311-20. doi: 10.1002/sim.2685.
3
A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.二维剂量探索试验设计与分析的非参数方法
Stat Med. 2004 Jun 30;23(12):1861-70. doi: 10.1002/sim.1796.
4
Parametric modeling of DSC-MRI data with stochastic filtration and optimal input design versus non-parametric modeling.
Ann Biomed Eng. 2007 Mar;35(3):453-64. doi: 10.1007/s10439-006-9218-1. Epub 2006 Dec 8.
5
Adaptive urn designs for estimating several percentiles of a dose--response curve.用于估计剂量-反应曲线多个百分位数的自适应瓮设计
Stat Med. 2004 Jul 15;23(13):2137-50. doi: 10.1002/sim.1808.
6
Predictive feedback in human simulated pendulum balancing.人类模拟摆锤平衡中的预测性反馈。
Biol Cybern. 2009 Aug;101(2):131-46. doi: 10.1007/s00422-009-0325-6. Epub 2009 Jul 9.
7
Classification based on hybridization of parametric and nonparametric classifiers.基于参数化和非参数化分类器杂交的分类方法。
IEEE Trans Pattern Anal Mach Intell. 2009 Jul;31(7):1153-64. doi: 10.1109/TPAMI.2008.149.
8
Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data.非正态分布数据的随机试验分析中的参数统计与非参数统计
BMC Med Res Methodol. 2005 Nov 3;5:35. doi: 10.1186/1471-2288-5-35.
9
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.转基因植物及其衍生食品和饲料的安全性与营养评估:动物饲养试验的作用
Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13.
10
Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.非癌症II期试验中剂量探索的适应性设计:早期意外结果的影响。
Clin Trials. 2008;5(6):595-606. doi: 10.1177/1740774508098788.

引用本文的文献

1
Isotonic Phase I cancer clinical trial design utilizing patient-reported outcomes.利用患者报告结局的等渗I期癌症临床试验设计
Stat Biopharm Res. 2025;17(1):36-45. doi: 10.1080/19466315.2023.2288013. Epub 2024 Jan 5.
2
The Correlated Beta Dose Optimisation Approach: Optimal Vaccine Dosing Using Mathematical Modelling and Adaptive Trial Design.相关β剂量优化方法:使用数学建模和适应性试验设计的最佳疫苗剂量确定
Vaccines (Basel). 2022 Oct 30;10(11):1838. doi: 10.3390/vaccines10111838.
3
Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
Surv-CRM-12:用于右删失毒性终点和竞争疾病进展的贝叶斯 I/II 期生存 CRM
Stat Med. 2022 Dec 20;41(29):5753-5766. doi: 10.1002/sim.9591. Epub 2022 Oct 19.
4
Dose finding studies for therapies with late-onset toxicities: A comparison study of designs.晚期毒性治疗的剂量发现研究:设计比较研究。
Stat Med. 2022 Dec 30;41(30):5767-5788. doi: 10.1002/sim.9593. Epub 2022 Oct 17.
5
Bayesian Sample Size Planning Tool for Phase I Dose-Finding Trials.贝叶斯一期剂量探索试验样本量计划工具。
JCO Precis Oncol. 2022 Aug;6:e2200046. doi: 10.1200/PO.22.00046.
6
Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.将连续评估法扩展到适应 I 期试验中的逐步加量给药。
Stat Med. 2022 Sep 10;41(20):3975-3990. doi: 10.1002/sim.9487. Epub 2022 Jun 5.
7
CFO: Calibration-free odds design for phase I/II clinical trials.无校准似然比设计在 I/II 期临床试验中的应用。
Stat Methods Med Res. 2022 Jun;31(6):1051-1066. doi: 10.1177/09622802221079353. Epub 2022 Mar 3.
8
Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic.大流行期间实施贝叶斯自适应 I 期设计的实用建议。
BMC Med Res Methodol. 2022 Jan 20;22(1):25. doi: 10.1186/s12874-022-01512-0.
9
Operating characteristics are needed to properly evaluate the scientific validity of phase I protocols.操作特性是正确评估 I 期方案科学有效性所必需的。
Contemp Clin Trials. 2021 Sep;108:106517. doi: 10.1016/j.cct.2021.106517. Epub 2021 Jul 25.
10
Seamless phase I/II design for novel anticancer agents with competing disease progression.具有竞争疾病进展的新型抗癌药物的无缝 I/II 期设计。
Stat Med. 2021 Sep 20;40(21):4568-4581. doi: 10.1002/sim.9080. Epub 2021 Jul 2.